0．1％他扎罗汀乳膏短时接触疗法治疗面部痤疮疗效观察

目的：观察0．1％他扎罗汀乳膏短时接触疗法治疗轻、中度面部寻常痤疮的临床疗效和安全性。方法：采用随机、单盲及平行对照的临床研究方法分组观察比较0．1％他扎罗汀乳膏短时接触疗法与常规疗法治疗面部痤疮的疗效和安全性。结果：治疗组24例患者外用0．1％他扎罗汀乳膏短时接触疗法后2周、4周和8周的有效率分别为25．0％、41．7％及70．8％，对照组24例患者外用0．1％他扎罗汀乳膏常规疗法疗后2周、4周和8周的有效率分别为20．8％、45．8％及75．0％，两组疗效差异无统计学意义；治疗组与对照组的不良反应发生率分别为4．2％及29．6％，治疗组不良反应发生率显著低于对照组（P〈0．05）。结论：0．1％他扎罗汀乳膏短时接触疗法治疗轻、中度面部寻常痤疮疗效好，不良反应少，有很好的耐受性。     

他扎罗汀凝胶与阿达帕林凝胶治疗寻常性痤疮的临床观察

我们于2004年2～9月对本院痤疮门诊78例面部寻常性痤疮患者进行了0．1％他扎罗汀凝胶短接触法和0．1％阿达帕林（达芙文）凝胶治疗面部痤疮的随机对照临床实验，取得满意疗效，现总结报道如下。     

红蓝光联合他扎罗汀治疗面部寻常型痤疮60例临床观察

目的评价红蓝光联合他扎罗汀治疗面部寻常型痤疮的临床效果和安全性。方法将入选的179例寻常型痤疮患者随机分为三组,对照1组(60例)予红蓝光治疗,对照2组(59例)予他扎罗汀治疗,治疗组(60例)予红蓝光联合他扎罗汀治疗,比较三组患者的临床疗效和不良反应。疗程均为8周。结果对照1组、对照2组、治疗组的有效率分别为71.67%,79.66%和95.00%。治疗组的有效率均高于其他两组,差异均有统计学意义(P均0.01)。另外,三组患者的不良反应发生率差异无统计学意义(P0.05)。结论红蓝光联合他扎罗汀治疗面部寻常型痤疮疗效好,不良反应轻。     

他扎罗汀凝胶外用联合NB-UVB治疗斑块状寻常型银屑病的疗效观察

目的：观察他扎罗汀凝胶外用联合NB-UVB照射治疗斑块状寻常型银屑病的疗效及安全性。方法：对35例轻、中度患者采用0．05％他扎罗汀凝胶每晚1次外涂配合NB-UVB每周2次照射，共治疗8周，用PASI积分评价疗效。结果：治疗开始1～2周后出现疗效，随着治疗时间的延长。有效率逐渐提高，治疗结束时痊愈率达到94．29％，有效率达100％。6例发生皮肤刺激反应，占17．14％。结论：他扎罗汀凝胶外用联合NB-UVB照射治疗斑块状寻常型银屑病具有良好疗效和安全性。     

0．1％他扎罗汀乳膏联合过氧苯甲酰凝胶治疗寻常型痤疮疗效观察

目的：了解他扎罗汀乳膏联合过氧苯甲酰凝胶治疗痤疮的临床疗效。方法：将120例病例随机分为A、B、c三组，A组外用他扎罗汀乳膏，B组外用过氧苯甲酰凝胶，c组白天外用过氧苯甲酰凝胶，晚上外用他扎罗汀乳膏，于初诊及治疗后2、4、6、8周复查，并记录皮疹消退情况及副作用，8周为一疗程。结果：A组和B组有效率比较差异无统计学意义，A组和c组、B组和c组有效率比较差异有统计学意义。结论：0．1％他扎罗汀乳膏联合过氧苯甲酰凝胶治疗寻常型痤疮疗效优于单独外用他扎罗汀乳膏或单用过氧苯甲酰凝胶。     

0．1％他扎罗汀乳膏治疗寻常痤疮疗效观察

为了观察0．1％他扎罗汀乳膏[商品名：乐为，重庆华邦制药有限公司生产]治疗寻常痤疮的疗效和安全性，我们于2005年10月至2006年10月期间对44例轻、中度面部寻常痤疮患者进行治疗，现报告如下：     

0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响

目的:评价0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响及其安全性.方法:采用多中心、随机、双盲、安慰剂对照方法,对纳入观察的126例经治疗后症状缓解达到Pillsbury分级法属I级以下的寻常痤疮患者.采用0.1%他扎罗汀乳膏(或安慰剂)短时接触隔日维持治疗,按Doshi的痤疮综合分级系统(the global ache grading system,GAGS)计分评价,观察维持疗程第4、8、12周症状变化情况,评估其对症状复发的影响.结果:0.1%他扎罗汀乳膏维持治疗组较安慰剂组的复发率明显降低,在随访的第8和12周复发率差异有统计学意义(χ~2=5.255和8.147,P<0.05);两组无论是轻、中、重度,还是局部不良反应发生率均相近,发生率极低.总的局部不良反应发生率(3.33%/1.69%)比较差异无统计学意义(χ~2=0.325、P>0.05).结论:0.1%他扎罗汀乳膏短时接触隔日维持治疗能减少寻常痤疮复发,且局部不良反应少,具有一定的临床应用价值.     

0.1%他扎罗汀乳膏短时接触治疗寻常痤疮的疗效观察

［目的］对比观察及评价0.1%他扎罗汀乳膏短时接触治疗与常规每日一次治疗轻中度寻常型痤疮的疗效和安全性。［方法］采用前瞻性开放性对照观察,选用重庆华邦公司0.1%他扎罗汀乳膏局部外用面部轻中度痤疮,短时接触疗法为每晚1次,5分钟后洗去,常规疗法为每晚1次过夜,疗程均为8周,于第1、2、4、8周进行复诊随访。短时接触治疗组为52例,常规治疗组为49例。［结果］第8周时0.1%他扎罗汀短时接触治疗组有效率为69.1%,常规治疗组有效率为75.1%,X2=6.501,P=0.09＞0.05,两组疗效之间无显著统计学差异。不良反应发生率短时接触治疗组为21.2%,常规治疗组为44.9%,X2=8.538,P=0.036＜0.05,两组不良反应发生率有显著统计学差异,短时接触治疗组明显低于常规治疗组。［结论］他扎罗汀短时接触治疗寻常型痤疮安全、有效,值得临床推广应用。     

皮脂腺及皮下脂肪疾病

育龄女性痤疮的内分泌水平测定及中医辨证治疗分析，0．05％他扎罗汀凝胶治疗寻常性痤疮临床疗效观察，青春痤疮片治疗寻常痤疮疗效观察，舒肤佳香皂和浴液对青少年轻、中度寻常痤疮的疗效观察，卡介菌多糖核酸等联合治疗重度集簇性痤疮，胸腺素注射液治疗痤疮疗效观察，     

阿维A胶囊联合他扎罗汀乳膏治疗中重度痤疮52例疗效观察

目的：观察阿维A胶囊联合他扎罗汀乳膏治疗中、重度痤疮的疗效。方法：治疗组口服阿维A胶囊10mg，每天2次，同时皮损外用0.1％他扎罗汀膏，每晚1次；对照组皮损仅外用0.1％他扎罗汀乳膏，每晚1次，两组疗程均8周。结果：治疗组总有效率为90．38％，对照组总有效率为60％，两组比较差异有统计学意义（X^2=11．13，P〈0．01）。结论：阿维A胶囊联合他扎罗汀乳膏治疗中重度痤疮疗效满意。     

Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.

Retinoids reverse the abnormal pattern of keratinization seen in acne vulgaris. Tazarotene is the first of a novel family of topical receptor-selective acetylenic retinoids. This study evaluates the safety and efficacy of topical tazarotene 0.1% and 0.05% gels, in comparison to vehicle gel, applied once daily for 12 weeks, in the treatment of mild-to-moderate facial acne vulgaris. A total of 446 patients with facial acne vulgaris were enrolled, and 375 patients, ranging in age from 14 to 44 years, were evaluable in this multicenter, double-blind, randomized study. In comparison to vehicle gel, treatment with tazarotene 0.1% gel resulted in significantly greater reductions in noninflammatory and total lesion counts at all follow-up visits, and inflammatory lesion counts at Week 12. Tazarotene 0.05% gel resulted in significantly greater reductions in noninflammatory and total lesion counts than vehicle gel at Weeks 8 and 12. At Week 12, treatment success rates were 68% and 51% for tazarotene 0.1% and 0.05%, respectively (40% for vehicle gel). Tazarotene gel was an effective, safe, and generally well-tolerated therapy for the treatment of acne vulgaris.     

Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel

CONTEXT: Short-contact application of 0.1% tazarotene gel for acne was devised to minimize local adverse effects. Its efficacy and safety are unknown. OBJECTIVES: To assess acne improvement and tolerability during 12 weeks of short-contact treatment with 0.1% tazarotene gel vs a nonmedicated gel control. DESIGN: A randomized, masked, vehicle-controlled trial. SETTING: Outpatient facilities at an urban medical school and an affiliated suburban office practice. PARTICIPANTS: Ninety-nine volunteers with facial acne were enrolled; 81 completed the study. INTERVENTION: Thirty-three patients were randomly assigned to each of 3 groups: T + T applied 0.1% tazarotene gel twice daily, T + V applied 0.1% tazarotene gel once daily and vehicle gel once daily, and V + V applied vehicle gel twice daily. Patients adjusted the contact period as tolerated, between 30 seconds and 5 minutes per application. MAIN OUTCOME MEASURES: Acne efficacy by reduction in acne lesions, treatment success (50%-100% improvement in global response to treatment) and improvement in overall disease severity. Local adverse effects, scored from none to severe. RESULTS: By week 12, T + T and T + V achieved significantly greater improvement in acne than V + V based on mean percentage reduction in noninflammatory lesions (46% and 41% vs 2%; P =.002) and inflammatory lesions (38% and 34% vs 9%; P =.01), percentage of treatment successes (64% and 61% vs 15%; P<.001), and reduction in overall disease severity (30% and 29% vs 3%; P<.001). Local adverse effects did not differ significantly among the 3 groups after week 4. CONCLUSION: Short-contact 0.1% tazarotene gel therapy is a safe and effective new method of acne treatment.     

阿达帕林凝胶联合过氧苯甲酰凝胶治疗寻常痤疮的多中心随机对照研究

目的评价阿达帕林凝胶联合过氧苯甲酰凝胶治疗轻中度寻常痤疮的疗效和安全性。方法随机、多中心、开放、平行对照研究。按照痤疮严重程度国际改良标准入选轻、中度寻常痤疮患者。试验组早晨外用5%过氧苯甲酰凝胶1次,晚睡前外用0.1%阿达帕林凝胶1次;对照组仅晚睡前外用0.1%阿达帕林凝胶1次。共用药12周,在基线、2、4、8和12周时记录炎性皮损、非炎性皮损和总皮损数,皮肤局部刺激反应如红斑、脱屑、干燥、烧灼/刺痛的评分,以及其他不良反应。结果3个中心共入选150例患者。试验组、对照组的总有效率在第8周分别为74.6%和56.7%(P<0.05);在第12周时分别为81.3%和68.9%(P>0.05)。局部刺激反应评分除烧灼/刺痛在第4、8周时两组间的差异有显著性外,其余差异均无显著性。另外,两组各有2例发生接触性皮炎。结论0.1%阿达帕林凝胶合用5%过氧苯甲酰治疗轻中度寻常痤疮较0.1%阿达帕林凝胶单用疗效显著,见效快,病程短,未增加不良反应。     

0.1%阿达帕林凝胶预防和减轻寻常痤疮复发的多中心随机对照临床试验

目的评价0.1%阿达帕林凝胶维持治疗对于预防和减轻寻常痤疮复发的作用.方法采用多中心、区组随机、开放、对照的方法,共入选患者246例,均为经过阿达帕林和克林霉素(特丽仙)联合治疗或特丽仙单独治疗获得有效(改善≥25%)的寻常痤疮患者,随机分为两组,一组外用0.1%阿达帕林凝胶,另一组不用药,均观察12周.结果239例患者完成治疗和观察,阿达帕林组121例,对照组118例.治疗4周后阿达帕林组炎性皮损数的减少显著优于对照组(P＜0.05),并维持至12周;治疗8周后阿达帕林组皮损总数和非炎性皮损数的减少也显著优于对照组(P＜0.01),并维持至12周.治疗结束后,阿达帕林组总体改善率为66.9%,对照组为4.2%(P＜0.01);阿达帕林组总复发率为4.1%,对照组为83.9%;两组间差异有显著性(P＜0.01).阿达帕林组有个别病例有轻度局部刺激反应,两组间不良反应差异无显著性(P＜0.05).结论阿达帕林凝胶可有效地治疗寻常痤疮,并维持治疗效果,且不增加局部刺激反应,对于减少病情复发具有显著效果.     

夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮的临床观察

目的评价2%夫西地酸软膏联合0.1%阿达帕林凝胶治疗轻、中度寻常痤疮的临床疗效及安全性。方法寻常痤疮246例,随机分为3组,治疗组98例,采用2%夫西地酸软膏联合0.1%阿达帕林凝胶治疗;对照A组81例,采用1%克林霉素磷酸酯凝胶联合0.1%阿达帕林治疗;对照B组67例,单独使用0.1%阿达帕林凝胶治疗。均连用8周,分别在治疗后第2,4,8周末观察疗效并评价安全性。结果在治疗后第8周,治疗组有效率93.88%,与对照A组(81.48%)相比差异有统计学意义(P=0.010);治疗组Ⅲ级痤疮的有效率93.02%,与对照A组(69.70%)相比差异有统计学意义(P=0.007);疗程结束后,治疗组复发5例,复发率5.10%,远低于2个对照组。单独外用阿达帕林疗效均欠佳,且复发率较高。在治疗过程中,3组均未见明显不良反应。结论 2%夫西地酸软膏联合0.1%阿达帕林凝胶治疗轻、中度寻常痤疮具有疗效较好、复发率低、不良反应少等优点,是较理想的治疗方案。     

Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study

OBJECTIVE: To evaluate the efficacy of 3 maintenance regimens (topical tazarotene, oral minocycline hydrochloride, or both) in sustaining improvement in acne. DESIGN: Multicenter, open-label treatment phase followed by double-blind, randomized, parallel-group maintenance phase. SETTING: Ambulatory patients in research or referral centers. PATIENTS: Volunteer sample of 189 patients with moderately severe to severe acne vulgaris (110 entered maintenance phase, 90 completed, and 2 discontinued because of adverse events). INTERVENTIONS: All patients were treated with 0.1% tazarotene gel (each evening) and a 100-mg capsule (twice daily) of minocycline hydrochloride for up to 12 weeks. Patients with 75% or greater global improvement at week 12 were randomly assigned to 12 weeks of maintenance therapy with tazarotene gel plus placebo capsules, vehicle gel plus minocycline capsules, or tazarotene gel plus minocycline capsules. MAIN OUTCOME MEASURES: Overall disease severity, global improvement, and lesion counts. RESULTS: All regimens were effective in sustaining improvements in acne. After 12 weeks of maintenance therapy, the mean reductions from baseline in noninflammatory and inflammatory lesion count, respectively, were 60% and 54% with tazarotene, 52% and 66% with minocycline, and 64% and 66% with tazarotene plus minocycline. At week 24, more than 80% of patients in each group had maintained a 50% or greater global improvement from baseline, and more than 50% had maintained a 75% or greater global improvement. CONCLUSIONS: A high percentage of patients with moderately severe to severe acne can maintain improvement in their condition with topical retinoid monotherapy. Maintenance with combination tazarotene and minocycline therapy showed a trend for greater efficacy but no statistical significance vs tazarotene alone. Topical retinoid monotherapy should be considered for maintenance to help minimize antibiotic exposure.     

Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris

Topical retinoids are the cornerstone of therapy for acne vulgaris. Nevertheless, the adjunctive use of other anti-acne agents can help enhance the efficacy of topical retinoids still further. Given that tazarotene 0.1 percent gel has previously shown significantly greater efficacy than tretinoin 0.025 percent gel, it is likely that tazarotene plus clindamycin offers superior efficacy to tretinoin plus clindamycin, which has recently become available as a combination product. A total of 150 patients with facial acne vulgaris were randomly assigned to receive either tazarotene 0.1 percent cream plus clindamycin 1 percent gel, or tretinoin 0.025 percent gel plus clindamycin 1 percent gel. Each medication was applied once daily in the evening (clindamycin followed by the retinoid 5-10 minutes later) for up to 12 weeks. At week 12, the reduction from baseline in lesion counts was greater with tazarotene/clindamycin than tretinoin/clindamycin for both the non-inflammatory lesion count (71% vs. 52%, p< or =.01) and the inflammatory lesion count (77% vs. 67%, P=.053). Tazarotene/clindamycin also resulted in a significantly higher incidence of patients achieving > or = 50 percent global improvement (incidence of 88% vs. 75% at week 12; p< or =.05). Both regimens were similarly well tolerated. In the treatment of facial acne vulgaris, tazarotene plus clindamycin offers significantly greater efficacy than tretinoin plus clindamycin and has comparable tolerability.     

Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study.

OBJECTIVES: To compare the efficacy and tolerability of tazarotene plus hydroquinone versus tazarotene alone in the treatment of facial photodamage. METHODS: Patients with facial mottled hyperpigmentation of at least moderate severity and an overall integrated assessment of photodamage score of at least moderate applied tazarotene 0.1% cream each evening and either hydroquinone 4% cream or placebo cream each morning for up to 24 weeks. RESULTS: Among 131 patients enrolled, 114/124 (92%) with exit data completed. Both regimens were highly effective in reducing photodamage, with tazarotene plus hydroquinone showing superiority over tazarotene alone for some efficacy measures. The incidence of >or=1-grade improvement from baseline (on a scale of none, minimal, mild, moderate, or severe) was significantly greater with tazarotene plus hydroquinone than with tazarotene alone for lentigines (weeks 12-24, por=50% global improvement was also significantly superior with the combination regimen as early as week 8 (p相似文献